Drug Profile
KP 470
Alternative Names: KP-470Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Psoriasis in Japan (Topical)
- 17 May 2021 KP 470 is no longer licensed to Bausch Health Companies in Canada, Europe and USA
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies